Association of metabolic syndrome with serum fibroblast growth factor 21 in kidney transplanted patients

Leila Bagheri ¹, Maryam Hami ¹ * , Mohammad-Javad Mojahedi ¹, Mahin Ghorban Sabbagh ¹, Hosein Ayatollahi ²

Cited by CrossRef: 5

1- Lin S, Yu L, Ni Y, He L, Weng X, Lu X, Zhang C. Fibroblast Growth Factor 21 Attenuates Diabetes-Induced Renal Fibrosis by Negatively Regulating TGF-β-p53-Smad2/3-Mediated Epithelial-to-Mesenchymal Transition via Activation of AKT. Diabetes Metab J. 2020;44(1):158 [Crossref]

2- Bartmańska M, Wiecek A, Adamczak M. Plasma FGF21 Concentration in Kidney Transplant Patients—Results from Prospective and Cross-Sectional Studies. JCM. 2024;13(14):4266 [Crossref]

3- Choi J, Kim J, Park I, Huh J, Kim K, Cha S, Park K, Sohn J, Park J, Koh S. Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study. Yonsei Med J. 2018;59(2):287 [Crossref]

4- Goldmannová D, Spurná J, Krystyník O, Schovánek J, Cibičková L, Karásek D, Zadražil J. Adipocytokines and new onset diabetes mellitus after transplantation. J Appl Biomed. 2018;16(4):247 [Crossref]

5- Guo Y, Li L, Hu S. Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: a meta-analysis. Renal Failure. 2023;45(1) [Crossref]